NCT Number: NCT06726915
Effect of Different Maternal Hemoglobin and Hematocrit Values on Perinatal Outcome
This study aims to evaluate the perinatal outcome in pregnancies with different levels of hemoglobin/hematocrit to verify which category of women should have iron supplementation if not all.
Trial opening soon.
Get NotifiedKey information
Age range
18 year and older
Sex eligibility
Female
Study type
Observational
About this study
Anaemia in pregnant women has been reported to have various adverse effects on both the mother and unborn foetus. These effects include preterm birth, a low birth weight and an increase in the risk of maternal and perinatal mortality . Postpartum anaemia impairs wound healing, increases the risk for readmission and/or prolonged hospitalization, and increases the cost of care for families .
Some investigators stated adverse perinatal outcome in pregnant mothers with high haemoglobin and haematocrit values and raised a question about the possible harmful effect of iron supplementation in such pregnancies.
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- 1. Pregnant women scheduled for labor or C.S (at term, 28-42 weeks). 3. Singleton pregnancy. 4. Age range: 18-40 years. 5. Willing to provide informed consent for participation and follow-up.
Exclusion criteria
- Refusal to participate or consent.
- Presence of non-iron deficiency anemia (e.g., hemoglobinopathies, chronic disease-related anemia).
- Multiple pregnancies (e.g., twins or more).
- Antepartum hemorrhage (e.g., placenta previa, placental abruption).
- PAS.
- Malformed fetus. -
Treatment and study plan
Primary outcomes
-
Fetal weight measurement- still birth or major morbidity
Time frame: Baseline
Secondary outcomes
-
Maternal needs for iron therapy
Time frame: Baseline
-
. Un-even postpartum period: Failure of lactation- DVT- CS wound complications Postpartum anaemia
Time frame: Baseline
Study contacts
Contact information is provided by the study sponsor or research team.
Ali Mohamed Ammar, Graduate
CONTACT
Hassan Salah Kamel
CONTACT
Sponsors and collaborators
Lead sponsor
Ali Mohamed Mohamed Ammar
Other
Registry information
Important dates
- Study start
- 2025
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Dec 10, 2024
- Registry last updated
- Dec 10, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.